Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

Gilead Sciences and Yescarta®
By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology and its FDA approved therapy Yescarta.  At the ASCO 2019 two new analyses were presented from the ZUMA-1 clinical trial of Yescarta®  in adult patients with relapsed or . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.